J.M. Kaplan Fund
Through its Furthermore program, the J.M. Kaplan Fund supports nonfiction books about the urban experience; natural and historic resources; art, architecture, and design; cultural history; and civil liberties and other public issues.
The program seeks work that appeals to an informed general audience; demonstrates evidence of high standards in editing, design, and production; promises a reasonable shelf life; might not otherwise achieve top quality or even come into being; and "represents a contribution without which we would be the poorer."
Individual grants range from $500 to approximately $15,000 and may be used to support writing, research, editing, design, indexing, photography, illustration, and/or printing and binding.
See the Furthermore website for complete application guidelines and program information.
Department of Defense
OFFICE OF STRATEGIC INITIATIVES - CALL FOR SUBMISSIONS
U.S. Army Medical Research and Materiel Command (USAMRMC) Broad Agency Announcement - BAA -15-1
Apply early. Funding is limited and subject to availability.
The BAA is continuously open, and accepts proposals on a rolling basis. Pre-proposals may be submitted and will be evaluated at any time throughout the year.
Scope: The USAMRMC's mission is to provide solutions to medical problems of importance to the American warfighter. Projects must pertain to at least one of the research areas of interest outlined in the BAA.
Funding: Budgets are not capped and must reflect the scope of the work. Funding can be requested for up to 5 years.
Areas of interest:
1. Military Infectious Diseases Research Program
2. Combat Casualty Care Research Program
3. Military Operational Medicine Research Program
4. Clinical and Rehabilitative Medicine Research Program
5. Medical Biological Defense Research Program
6. Medical Chemical Defense Research Program
7. Medical Simulation and Information Sciences Research Program
8. Radiation Health Effects Research Program
9. Special Investment Areas/Innovation Funding
Office of Strategic Initiatives (OSI): Case School of Medicine's OSI can work with you to make sure that you meet the current goals and objectives of the USAMRMC that is paramount for your success. OSI can assist you in preparing a competitive proposal and can help guide your efforts from the first draft of the pre-proposal to submission of the full application.
Timeline: Invitation to submit a Full proposal will be given within 90 days of submission of the pre-proposal. An additional 90 days is provided to the applicant to complete the full application. Allow for at least 6 months between submission of the whitepaper to submission of the full application.
Contact us: If you are planning on submitting a pre-proposal, have questions, or would like more information - contact OSI Project Manager Irene Shaland - email@example.com - 216.368.4970
Foundation Fighting Blindness and Harrington Discovery Institute
Foundation Fighting Blindness and Harrington Discovery Institute have partnered to form, the The National Center for Excellence in Fighting Blindness, a Gund-Harrington initiative. This initiative is focused on accelerating the translation of research findings in inherited retinal degenerative diseases (IRD) with the ultimate goal of developing new therapies to improve and/or restore vision.
• This Initiative seeks to award Gund-Harrington Scholar Awards that recognize innovators throughout the USA whose research has the potential to advance standards of care.
• There will be an average of three awards per year, which will be restricted to researchers working at institutions within the USA. Applications from outside the USA are not accepted.
• The Gund-Harrington Scholar Award provides funding for translational drug development and cell therapy along with non-financial project support to help bridge the gap between laboratory-based research and the clinic.
• Funding up to a total of $900,000 over three years and non-financial support will be provided by the The National Center for Excellence in Fighting Blindness. The non-financial support, provided by a team of pharmaceutical experts, will include project management and experienced industry advice in all aspects of drug development, encompassing chemistry, formulation, toxicology, regulatory, intellectual property and business development.
• Awards will be made to physician-scientists, or scientists with a research team that includes significant involvement of a physician with clinical expertise in the IRD.
• Selected projects must demonstrate a reasonable expectation that they can develop a lead product with strong potential for clinical and commercial application by the end of the three year funding period.
• Multi-disciplinary investigators outside the field of retinal disease are particularly encouraged to apply.
Applicants interested in the Gund-Harrington Scholar Awards must apply through Foundation Fighting Blindness.
For more information about Foundation Fighting Blindness visit the Fighting Blindness website.
Division of Infectious Diseases & HIV Medicine, CWRU and UH Case Medical Center
Announcement of Infectious Diseases Research Support from STERIS Corporation
The Division of Infectious Diseases & HIV Medicine at Case Western Reserve University and University Hospitals Case Medical Center, with funds from STERIS Corporation, will provide seed money to faculty to foster research in emerging and healthcare-associated infections.
Announcement of Infectious Diseases Research Support from the Infectious Diseases & Immunology Institute (IDII)
The Infectious Diseases & Immunology Institute (IDII) at Case Western Reserve University will provide seed money to young investigators (within 5 years of appointment) to foster interdisciplinary research in infectious diseases and immunology.
For more information on these opportunities, please contact Martha Salata at 844-1988 or firstname.lastname@example.org or visit the Center’s website.
The Ohio Clinical Trial Collaborative (OCTC)
The Ohio Clinical Trial Collaborative OCTC is developing partnerships with the drug industry to include Biotech and Pharmaceutical industries to perform clinical drug trials phase I-4. The OCTC is a network of Ohio based hospitals led by working groups in areas such as neuro oncology, pediatrics, infectious disease, and neuroscience. The OCTC was launched at the BIO2014 which was attended by 15,000 biotech and pharmaceutical executives in San Diego resulting in numerous leads for potential drug trials.
The OCTC has plans to attend additional biotech and pharmaceuticals shows. The OCTC is looking for additional working groups interested in developing a sell sheet that can then be searched on the World Wide Web and will begin sales and marketing activities to identify opportunities with industry. If there are companies that individuals would like OCTC to target, the group welcomes that feedback.
Review the OCTC working website at: http://ohioclintrials.org.
Contact Joe Peter at 216-702-5314 for more information.
If you have news or information that you wish to have included in this
update, please send it via e-mail to Tracy Wilson-Holden at
email@example.com no later than
5 pm on the Monday of the week that the update is to be distributed. If you
know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe
to Case Research News, email your request to Tora Williams at
Please note: At the time of this transmission, all links functioned.
However, Case Research News cannot guarantee that the information will not move or be